0000000000699618
AUTHOR
M. Dolores Esteve-gassent
Efficacy of oral reimmunisation after immersion vaccination against Vibrio vulnificus in farmed European eels
Abstract Vulnivaccine, a licensed vaccine against Vibrio vulnificus , protects eels against vibriosis after vaccination by triple prolonged immersion at glass eel stage. Protection lasts for at least 6 months, but later, protection decreases, and eels can suffer stress-related vibriosis. The main objective of this work was to design an oral vaccine that can be used for reimmunisation at any developmental eel stage. With this aim, the efficacy of Vulnivaccine mixed with food as an oral booster was tested in an eel farm. The protection and the immune response (innate and acquired) in serum, mucus (from skin and intestine) and bile were evaluated in reimmunised and control animals (non-reimmun…
Immunogenic antigens of the eel pathogen Vibrio vulnificus serovar E.
Abstract The immunogenic antigens of Vibrio vulnificus serovar E were investigated in the eel. Fish were vaccinated by immersion with Vulnivaccine (V), revaccinated 2 years later by intraperitoneal injection (RV) and bath infected 15 days post-revaccination (RVI). The specific immune response in serum was followed in all groups, and selected sera were used for immunostaining of surface (SA) and extracellular antigens (ECA). Bacteria were grown in iron-rich (TSB and MSWYE) and iron-poor media (TSB and MSWYE plus human transferrin (TSB-T and MSWYE-T)) as well as eel serum (ES), and their SA and ECA were extracted and electrophoretically analysed. Cells grown in MSWYE-T and ES presented the sa…